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ABSTRACT Infection-induced activation of the human
cytomegalovirus major immediate early enhancer/promoter
has been shown to be regulated primarily by transcription
factor NF-KB cis elements. However, the mechanism(s) by
which human cytomegalovirus induces NF-mcB activity is un-
known. A study was therefore undertaken to determine how
this virus would affect normal NF-#cB regulation. Viral infec-
tion of fibroblasts resulted in the specific stimulation of pro-
moters containing major histocompatibility complex NF-#cB cis
elements fused upstream of the chloramphenicol acetyltrans-
ferase reporter gene. Electrophoretic mobility shift assays of
nuclear extracts derived from mock- and virus-infected cells
showed dramatic and sustained increases in DNA-binding
proteins specific for these NF-KB sequences. Experiments using
MAD-3 lKB, a specific inhibitor of NF-ucB, and antibodies
directed against rel family members demonstrated that the
induced binding activities contained p5O and p65 proteins but
not c-rel. Northern analysis indicated maximal levels of p5O
mRNA by 4 h postinfection, whereas p65 and MAD-3 IicB
mRNA accumulation peaked at 48-72 h postinfection, suggest-
ing different regulatory mechanisms for p5O and p65/IicB
genes. Electrophoretic mobility shift assays with deoxycholate-
treated cytoplasmic extracts demonstrated a 3- to 4-fold de-
crease in the cytosolic stores of NF-#cB binding activity by 4 h
postinfection. Western blots probed with antibodies directed
against MAD-3 IicB or pp4O (a protein isolated from chicken
with sequence and biochemical properties similar to those of
MAD-3 IncB) indicated that a cross-reactive peptide of 39 kDa
was no longer detectable after 24 h postinfection. These results
demonstrate that the activation and maintenance of nuclear
NF-icB DNA binding and enhancer activities upon human
cytomegalovirus infection occurs by multiple mechanisms.
Human cytomegalovirus (HCMV) is a ubiquitous herpesvi-
rus associated with developmental abnormalities and is often
a pathogen in immunocompromised hosts (for review, see
ref. 1). HCMV gene expression is coordinated into three
tiers: immediate early (IE), early, and late. The major IE
product, IE1, is under the control of a powerful enhancer/
promoter, the major IE (MIE) promoter. Regulation of this
promoter is complex, entailing positive, negative, and cell
type-specific enhancer elements (2-5). Of these, the 18-bp
repeat element has been shown to be central to the activation
of the MIE promoter in productive infections of human
fibroblasts (3, 6, 7). Furthermore, the IE1 gene product
positively autoregulates the MIE promoter via the 18-bp
repeats (6). Each of the four 18-bp repeats contains a con-
sensus sequence for transcription factor NF-KB (GG-
GACTTTCC or GGGATTTCC), and previous work has
demonstrated an HCMV infection-induced DNA-binding ac-
tivity specific for the 18-bp repeat that is similar to the NF-KB
activity observed in phorbol 12-myristate 13-acetate- and
phytohemagglutinin-stimulated Jurkat cells (7). How HCMV
infection alters the normal cellular regulation of this apparent
NF-KB activity is not known.
NF-KB is a pleiotropic DNA-binding activity involved in
inducible gene expression. It is one of several related DNA
binding activities, which are composed of proteins in the rel
family (for review, see ref. 8). NF-KB was originally de-
scribed as an enhancer activity specifically associated with
activated expression of the K light chain in differentiated B
cells (9). NF-KB DNA binding activity is composed of two
proteins, p65 and p50, whereas another activity, KBF-1, is
composed of only p50 homodimers (10). Other rel family
proteins include c-rel and p49 (pSOB), both of which interact
with NF-KB enhancer sequences (8).
In most cell types, including fibroblasts, NF-KB is in an
inactive state associated with IKB (11, 12). Originally, two
forms of IKB were identified, IKBa and -,8 (13), each capable
of inhibiting NF-KB DNA-binding activity. Recently, a
cDNA (MAD-3) isolated from human monocytes whose gene
product has properties of IKB has been identified. At this
time, it is unclear whether MAD-3 is the a, the f3, or an
additional form of IKB, but partial peptide sequence data
from IKBa suggests that the MAD-3 gene product is IKBa
(14-19). In the current model, IKB sequesters NF-KB in the
cytosol in an inactive complex, which can respond to appro-
priate stimuli such as tumor necrosis factor or cytokines (20).
NF-KB activation occurs by an ill-defined mechanism that
releases NF-KB from IKB, permitting the translocation of
NF-KB into the nucleus where it can stimulate the transcrip-
tion of promoters containing NF-KB cis elements. The utility
of this system is in its ability to rapidly and transiently
respond to signals without de novo protein synthesis.
We report here that HCMV infection results in sustained
nuclear NF-KB activity and transactivation of promoters
containing NF-KB enhancer sequences. This activation is
initiated by the release of cytosolic stores of NF-KB. The
increased nuclear NF-KB activity is apparently maintained
over the course of virus infection by increasing the mRNA
levels for p50 and p65. In addition, steady-state levels of
MAD-3 IKB protein are diminished to undetectable levels at
later times of infection even though MAD-3 mRNA is in-
duced. Together, these results suggest that HCMV utilizes
multiple mechanisms to activate and sustain nuclear NF-KB
activity necessary for a productive viral infection.
MATERIALS AND METHODS
Virus and Cells. HCMV Towne strain was propagated and
titrated as described (21). Normal human foreskin fibroblasts
Abbreviations: HCMV, human cytomegalovirus; MHC, major his-
tocompatibility complex; CAT, chloramphenicol acetyltransferase;
IE, immediate early; EMSA, electrophoretic mobility shift assay;
hpi, hour(s) postinfection; NHF, normal human foreskin fibroblasts;
MIE, major IE; GST, glutathione S-transferase.
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(NHF) were kindly provided by W. Kaufman (University of
North Carolina at Chapel Hill) and maintained as described
(22). Cells were infected with HCMV at a multiplicity of
infection of 5 and absorbed for 2 h at 370C.
Transfection and Chloramphenicol Acetyltransferase (CAT)
Assays. DNA was transfected into cells (5 jig) by the Lipo-
fectin method (BRL) as described by the manufacturer. After
transfection, duplicate plates were infected with HCMV; the
cells were incubated for 48 h and assayed for CAT activity as
described (22, 23). The c-fos minimal promoter-CAT con-
structs (A56) containing three copies of wild-type (TGGG-
GATTCCCCA) or mutant (TGCGGCTTCCCQA) NF-KB
sequences from the major histocompatibility complex (MHC)
class I enhancer have been described (24).
Nuclear and Cytosolic Extract Preparation. Nuclear and
cytosolic extracts of mock- and HCMV-infected NHF cells
were prepared as described (22, 25).
Electrophoretic Mobility Shift Assays (EMSAs). EMSAs of
nuclear extracts and radiolabeled DNA probes were per-
formed as described elsewhere (24, 26). The NF-KB wild-type
and mutant probe sequences were those used in the promoter-
CAT constructs. In the indicated experiments, extracts were
preincubated for 10 min at room temperature with either
glutathione S-transferase (GST)-MAD-3 IKB or specific anti-
bodies prior to the addition ofprobe and subsequent EMSAs.
Bacterial Expression ofMAD-3 IKB. A cDNA representing
MAD-3 IKB was digested with EcoRI, ligated in-frame into
the EcoRI site ofpGEX-3X (Pharmacia), and transfected into
Escherichia coli. Protein expression and affinity purification
were as described (27). Functional activity of purified GST-
MAD-3 IKB was confirmed by specifically inhibiting the
DNA binding ofheteromeric complexes containing either p65
or c-rel (ref. 16; T.F.K., unpublished observations).
Northern Blot Analysis. Total RNA from mock- and
HCMV-infected NHF cells was resolved by formaldehyde/
agarose electrophoresis and blotted to nitrocellulose mem-
branes. Blots were hybridized with cDNAs representing p65
(ref. 28; a gift from C. Rosen, Roche Institute, Nutley, NJ),
plO5 (pSO) (ref. 29; kindly provided by A. Israel, Institut
Pasteur, Paris), and MAD-3 IKB (14).
Western Blot Analysis. Western blots were made and
processed as described (15).
RESULTS
HCMV Infection Enhances Promoter Transactivation via
NF-KB Elements. To demonstrate that HCMV infection re-
sults in the specific transactivation of promoters containing
characterized NF-KB cis elements, NHF cells were trans-
fected with the appropriate promoter-CAT constructs (24).
As shown in Fig. 1, a promoter containing essentially only a
TATA sequence (A56) was sufficient for transactivation by
HCMV infection. The ability to activate promoters contain-
ing only a TATA box upon HCMV infection has been
observed previously (30-32). The combination of wild-type
MHC NF-KB-promoter-CAT construct (MHC) and virus
infection resulted in a 12-fold stimulation of CAT activity
over that observed with A56 or a plasmid bearing mutant
NF-KB-CAT (MHC mut) sequences. Specific viral transac-
tivation through the 18-bp repeat of the HCMV major TE
enhancer/promoter region (which contains an NF-KB bind-
ing sequence) has also been observed (6, 7).
HCMV Infection Induces Nuclear DNA-Binding Proteins
Specific for NF-cB Sequences. To determine if the observed
enhanced promoter transactivation was associated with in-
creased nuclear DNA-binding proteins, nuclear extracts from
mock- and HCMV-infected fibroblasts were analyzed for
their ability to bind to NF-KB sequences. EMSAs of mock-
and virus-infected nuclear extracts using MHC NF-KB probe
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FIG. 1. HCMV infection results in enhanced promoter transac-
tivation via NF-KB cis elements. NHF cells were transfected in
duplicate with the appropriate CAT construct. Halfofthe plates were
subsequently infected with virus (+), and all of the plates were
incubated for an additional 48 h. Harvested cells were processed and
assayed (50 ,ug) for CAT activity. Acetylated forms of chloramphen-
icol were resolved by thin-layer chromatography, identified by
autoradiography, and quantitated by liquid scintillation spectrome-
try.
contained low levels of proteins capable of binding NF-KB
sequences by this assay; two complexes (II and III) were
apparent. However, large increases in retarded DNA were
observed by 12 h post-infection (hpi); at least four major
complexes of different mobilities were obtained (complexes
I-IV). These complexes are better differentiated in the
shorter exposures shown in Fig. 3. All four complexes
remained over the course of infection, although by 65 hpi the
levels of DNA binding had diminished somewhat (Fig. 2).
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FIG. 2. EMSA of nuclear extracts (7 M~g) from mock-infected or
infected NHF cells using double-stranded MHC NE-KB DNA as the
probe. Nuclear extracts were prepared from uninfected (mock) or
infected NHF cells at the times indicated. The four major complexes
observed in this and other EMSAs (Fig. 3) are numbered (I-IV), and
free probe is indicated. Lanes 2-4 have been overexposed to show
the presence of complexes II and III in lane 1.
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FIG. 3. Characterization of the major complexes observed in
EMSAs of HCMV-infected nuclear extracts. Radiolabeled MHC
NF-KB probe was used in each assay. (A) Competition assays using
wild-type and mutant competitor DNAs. Either a 0- (-), 5- (5x), 10-
(10x), or 50- (50x) fold excess of unlabeled competitor was incu-
bated with nuclear extract prior to the addition of radiolabeled probe
to the binding reaction. (B) Identification of proteins in retarded
complexes. Binding reactions were preincubated with nuclear ex-
tract alone (lane 1) or in the presence of GST-MAD-3 IKB (200 ng;
lane 2), anti-KBF-1 antiserum (antibody 3; kindly provided by A.
Israel, Institut Pasteur, Paris; lane 3), or anti-rel antiserum (gift from
N. Rice, Frederick Cancer Center, Frederick, MD; lane 4). In lane
5, a combination of IKB and anti-KBF-1 antiserum was used to
enhance the KBF-1 supershift (Ills). After the appropriate preincu-
bations in A and B, MHC NF-KB probe was added and assayed as in
Fig. 2.
This is in contrast to the more transient nuclear NF-KB
binding activity observed in serum-stimulated mouse 3T3
fibroblasts (24, 33).
Competition experiments with excess wild-type or mutant
NF-KB sequences in EMSAs are shown in Fig. 3A. The
addition of a 50-fold excess of unlabeled MHC NF-KB DNA
completely blocked by competition all but one (complex IV)
ofthe shifted complexes (Fig. 3A, lane 4). Complex I was also
poorly blocked by wild-type NF-KB sequence; it required
more than a 10-fold excess of unlabeled competitor. How-
ever, the formation of the other two complexes (II and III)
was readily blocked by a 10-fold excess of unlabeled DNA
(Fig. 3A, lane 3). Competition with excess mutant NF-KB
sequences resulted in minimal decreases in complexes I, II,
and IV and increased binding of complex III (Fig. 3A, lanes
6-8). The several minor complexes migrating with mobilities
slower than complex I were blocked by competition with
both wild-type and mutant NF-KB sequences and were not
further characterized.
IKB and antibodies were added to DNA-binding reactions
to determine which proteins were involved in specific binding
to the wild-type NF-KB sequence and presumably associated
with enhanced CAT activity afterHCMV infection. Inclusion
of bacterially expressed GST-MAD-3 IKB in the DNA-
binding reaction resulted in the disappearance of complex II
from nuclear extracts of virus-infected cells (Fig. 3B, lane 2).
This suggested that complex II contained either p65 or c-rel
because the DNA binding of these proteins has been shown
to be inhibited by the MAD-3 protein (14-16). Increased
levels of complex III were also observed in this experiment.
Similar results have been described elsewhere (15, 16). The
addition of antibodies that specifically supershift complexes
containing c-rel had no effect on any of the complexes
observed by EMSA (Fig. 3B, lane 4). Inclusion ofan antibody
that specifically supershifts p50/pSO DNA complexes
(KBF-1) resulted in the disappearance of complex III (Fig.
3B, lanes 3 and 5). As there was little complex III in the
infected nuclear extracts, the supershifted material was more
apparent after prolonged exposure of the gel to x-ray film.
That complex II was NF-KB (p50/p65), or a very similar
complex, was inferred by its dissolution by MAD-3 1KB, the
lack of interaction with the rel antibody, and comigration
with the NF-KB complex observed in phorbol ester-
stimulated HeLa and Jurkat cell nuclear extracts (T.F.K.,
unpublished observations).
The composition of complexes I and IV is not clear. The
competition experiments suggested that they were less spe-
cific than complex II and III. In fact, they comigrate with
nonspecific DNA-binding activities observed in phorbol es-
ter-stimulated Jurkat cells. However, their exact identity has
yet to be determined.
HCMV Infection Increases the Levels of mRNAs Encoding
p50, p65, and MAD-3 bIcB. Because the major HCMV infec-
tion-induced nuclear DNA-protein complex contained p50
and p65, Northern blots of total RNA from mock- and
HCMV-infected cells were probed with radiolabeled cDNAs
representing these two genes (Fig. 4). Maximal levels of p50
RNA were observed at 4 hpi and remained elevated over the
course of virus infection. This contrasts with the pattern
observed with p65 gene expression, where RNA levels grad-
ually increased over time and were maximal at 48-72 hpi,
suggesting that these two genes are differently regulated upon
HCMV infection. For comparison, blots were also probed for
expression of MAD-3 IKB mRNA. Accumulation of this
transcript displayed kinetics similar to p65 except that in-
creasing amounts of RNA were still being observed at late
times of infection (72 hpi). The increased levels of RNA
encoding p50 and p65 at these later times were likely the
p50U
p65
FIG. 4. HCMV infection increases steady-state levels of RNAs
representing p5O, p65, and 1KB. Mock- and HCMV-infected NHF
cells were harvested, and total RNA was prepared. The 0 hpi time
point was harvested immediately after virus absorption. A Northern
blot ofRNA from 5 x 105 cells per time point was sequentially probed
with nick-translated cDNAs encoding p5O (p105), p65, and MAD-3
1KB. RNA integrity was monitored by ethidium bromide staining and
UV visualization of duplicate lanes in the same agarose gel (not
shown).
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source of proteins for the sustained nuclear NF-KB binding
activities. This is true provided that the IKB transcripts
present at these time points were not translated or that the
resultant IKB protein was rapidly inactivated. These results
differ from previous studies in other systems where the
mRNA accumulation pattern for the p50 or IKB gene was
transient (14, 34-36).
Virus Infection Results in Decreased Cytosolic Stores of
p50/p65. Because the delayed expression ofp65 RNA did not
completely correlate with the early nuclear p5O/p65 activity
and the concomitant activation of MAD-3 IKB expression
would, in principle, sequester this DNA-binding activity,
cytosolic extracts of mock- and HCMV-infected cells were
assessed for the presence of p50/p65 stores. Upon treatment
of these extracts with deoxycholate (11), two complexes (Ic
and I1c) were observed by EMSA in all of the times points
tested (Fig. 5, lanes 1-5). Virtually no complexes were
observed without deoxycholate treatment (Fig. 5, lane 7).
Both complex Ic and complex 1Ic were reduced 3.5-fold in the
4 hpi cytosolic extract and remained suppressed relative to
mock-infected extracts in the later time points. A 3- to 4-fold
reduction between the mock and 4 hpi time points was highly
reproducible among assays and individual sets of cytosolic
preparations (T.F.K., unpublished observations). The mo-
bility of complex HIc was similar to the complex II observed
in infected nuclear extracts. Mobilities similar to complex Ic
were not observed in any of the nuclear extracts. The
inclusion ofGST-MAD-3 1KB in the binding reaction resulted
in disruption of both cytosolic complexes (Fig. 5, lane 6).
Together, these results suggest that the initial activation of
nuclear NF-KB binding activity is at least partly due to the
release of cytosolic stores ofNF-KB and the apparent nuclear
translocation of these components upon HCMV infection.
Virus Infection Alters the Levels of a 39-kDa Protein That
Cross-Reacts with Anti-MAD-3 IcB and Anti-pp4O Antisera. A
Western blot of mock- and HCMV-infected cell lysates was
probed with a polyclonal antiserum generated against an
N-terminal peptide of MAD-3 1KB (Fig. 6A). On the basis of
competition experiments with excess peptide, one protein of
39 kDa reacted specifically with the antibody (Fig. 6A). A
dramatic decrease of the steady-state levels of this protein
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FIG. 5. Characterization ofNF-KB binding activity in cytosols of
mock- and HCMV-infected NHF cells. Cytosols were prepared as
S100 extracts after cell lysis by Dounce homogenization, and the
extracts (3 gg) were analyzed by EMSA with the MHC NF-KB
sequence as the DNA probe. In lanes 1-5, cytosolic extracts were
pretreated with deoxycholate and Nonidet P-40 (11) prior to their
addition to the binding reactions. The EMSA shown in lane 6 was
processed in a manner similar to lane 1 except that GST-MAD-3 IKB
(200 ng) was included in the binding reaction. The EMSA of
mock-infected cytosolic extract in lane 7 was not pretreated with
detergents. Results similar to that observed in lane 7 were also





FIG. 6. Western blot assays for IKB in mock- and HCMV-
infected NHF cells. (A) Western blot probed with a polyclonal
antiserum developed against a peptide representing the N terminus
of MAD-3 IKB (antibody 9). Total proteins (20 lug) from mock- and
virus-infected NHF cells were resolved by SDS/10%7 PAGE, elec-
troblotted onto a nitrocellulose membrane, and probed with antibody
9. (B) Western blot using an anti-pp4O polyclonal antiserum (a gift
from H. Bose, University of Texas, Austin). Mock and 48 hpi
samples were the same as in A. Lane 3 contains purified MAD-3 1KB
(500 ng) expressed in bacteria (ref. 15; a gift from C. Rosen, Roche
Institute, Nutley, NJ).
occurred subsequent to 24 hpi. By 48-72 hpi, this protein
species could no longer be detected in this assay. In addition,
antiserum generated against pp40 (17), a protein isolated from
chicken and having sequence and biochemical properties
similar to MAD-3 IKB (17-19), was found to cross-react with
MAD-3 IKB (Fig. 6B). This antibody also recognized a
similarly sized protein in uninfected cell lysates, but little or
none was visible in lysates derived from cells 48 h after
HCMV infection (Fig. 6B). The disappearance of IKB pro-
tein(s) from infected cells, even though its mRNA levels have
increased, could explain the reduced cytosolic stores of
NF-KB (Fig. 4) and the presence of sustained levels ofnuclear
NF-KB at later times of infection (Fig. 2). However, IKB
would need to be inactivated through an additional mecha-
nism(s) at the earlier time points (compare Fig. 5, lane 2 with
Fig. 6A, lane 3). It seems plausible that the turnover of IKB
at later times of infection could be signaled by this initial
inactivation. Finally, at time points where little or no IKB
protein could be detected by the MAD-3 IKB and pp4O
antibodies, there were still significant cytosolic stores of
NF-KB, suggesting that there could be undetectable levels of
MAD-3 IKB remaining, or possibly the presence of immuno-
logically distinct IKB species that were resilient to inactiva-
tion upon HCMV infection.
DISCUSSION
In this study, we have shown that NF-KB is highly induced
in the nuclei of HCMV-infected fibroblasts. This activation
correlates with the specific transactivation of a promoter
containing NF-KB sequences. Induction of nuclear NF-KB by
virus infection is apparently the result of several factors: (i)
releasing the majority of the cytosolic stores of NF-KB, (ii)
increasing the levels of mRNAs encoding p50 and p65, and
(iii) removing IKB activity from the cell. The first two
mechanisms have been hypothesized as key control points in
the regulation of NF-KB. Temporally, cytosolic NF-KB ac-
tivity is released very early in the infection cycle. After
translocating to the nucleus, it activates expression of the
HCMV MIE genes and probably the gene encoding p50
(p105), each of which contains NF-KB binding elements in its
Proc. NatL Acad Sci. USA 90 (1993)
Proc. NatL. Acad. Sci. USA 90 (1993) 1111
promoter (7, 37). We and others have observed nuclear
NF-KB activity by 3-4-hpi (ref. 7; T.F.K., unpublished
observation) and, as herpesvirus IE genes are defined as
being transcriptionally active in the absence of protein syn-
thesis, the contribution of NF-KB to the activation of the
HCMV MIE promoter is further substantiated. That the
HCMV MIE promoter is dependent, at least initially, upon
NF-KB in a productive infection has been demonstrated (7).
This activation ofthe HCMV MIE promoter by NF-KB would
subsequently develop into a positive feedback loop in which
one of the gene products of the MIE region, IE1, stimulates
greater MIE promoter activity through the multiple 18-bp
repeats contained within this promoter. The activation ofp65
and MAD-3 IKB genes at later times suggests that their
promoters are regulated by different transcription factors.
Cloning of these promoters is needed to facilitate studies on
the separate and coordinate regulation of the p5O (p105), p65,
and MAD-3 IKB genes.
Recently, additional components involved in the NF-KB
system have been cloned. The mRNA of one factor, p49
(p100) or pSOB (38, 39), is not induced by HCMV infection
(T.F.K., unpublished observation). Inoue et al. (40) identi-
fied in lymphoid cell lines a spliced version of p105 mRNA
resulting in a protein with IKB activity. Although the 2.6-kb
mRNA for this protein was not observed in either mock- or
HCMV-infected fibroblasts (Fig. 4), a role for this IKB cannot
be ruled out at this point. Rivibre et aL (41) have demon-
strated that the human immunodeficiency virus protease can
process the inactive p105 precursor to an active 50-kDa form.
Activation of this NF-KB component by such a mechanism
needs to be addressed in the HCMV system.
Viral infection results in the disappearance of at least one
form ofIKB. The mechanism for this turnover is not apparent,
but it could possibly occur by signaling degradation through
the "PEST" sequence in the C-terminal half of MAD-3 1KB
(14). Regardless of the mechanism, there is a discrepancy
between the late turnover of MAD-3 IKB and the early
activation of cytosolic NF-KB. This suggests that an addi-
tional mechanism(s) to inactivate IKB may be involved.
Phosphorylation is a means by which IKB can be inactivated
in vitro (42) and, as HCMV has been shown to activate
signaling pathways associated with cytosolic kinases (43),
inactivation of IKB by phosphorylation in infected cells
remains a possibility.
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